Dual Innovations in EGFR Degradation and Antigen-Specific Modulation for Multiple Sclerosis.

Recent inventions have unveiled two complementary therapeutic strategies: cyclic peptides that trigger the lysosomal degradation of the epidermal growth factor receptor (EGFR), and soluble peptide-MHC constructs that suppress autoreactive T-cell receptors in multiple sclerosis. Together, these innovations highlight emerging frameworks for precision control of receptor signaling and adaptive immunity using structurally defined peptide modulators.